Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) – Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted pipeline therapeutics.

The report provides comprehensive information on the Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)

The report reviews Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics and enlists all their major and minor projects

The report assesses Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Biogen, Inc.

BioMAS Ltd.

MedImmune, LLC

Merck & Co., Inc.

SciFluor Life Sciences, LLC

Tissue Therapies Limited

TWi Pharmaceuticals, Inc.

Vascular Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Overview 8

Therapeutics Development 9

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Products under Development by Stage of Development 9

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Products under Development by Therapy Area 10

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Products under Development by Indication 11

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Products Glance 13

Late Stage Products 13

Early Stage Products 14

Unknown Stage Products 15

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Products under Development by Companies 16

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Products under Development by Universities/Institutes 18

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Therapeutics Assessment 20

Assessment by Monotherapy/Combination Products 20

Assessment by Mechanism of Action 21

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Companies Involved in Therapeutics Development 26

Biogen, Inc. 26

BioMAS Ltd. 27

MedImmune, LLC 28

Merck & Co., Inc. 29

SciFluor Life Sciences, LLC 30

Tissue Therapies Limited 31

TWi Pharmaceuticals, Inc. 32

Vascular Pharmaceuticals, Inc. 33

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Drug Profiles 34

264-RAD - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

AC-301 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Antibodies to Inhibit AlphaVBeta6 for Oncology - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

AS-101 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

BG-00011 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

C-16Y - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

cilengitide - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

MK-0429 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

OCU-200 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Melanoma - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Proagio - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

RSF-201 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

SF-0166 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Small Molecule to Antagonize AlphaVBetaI for Fibrosis - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Small Molecules to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

tetraiodothyroacetic acid - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

VF-001 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

VF-002 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

VF-003 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

VF-004 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

VPI-2690B - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Dormant Projects 57

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Discontinued Products 62

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Featured News & Press Releases 64

May 31, 2016: New Class of Protein Could Treat Cancer and Other Diseases, Georgia State Researchers Find 64

May 25, 2016: Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology 65

Mar 09, 2016: SciFluor Life Sciences Awarded Second U.S. Patent for Integrin avß3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease 65

Feb 11, 2016: Ocugen Announces Patent Allowance For Ocu-200 66

Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update 66

Feb 25, 2013: Merck Serono Announces Phase III Trial Of Cilengitide Did Not Meet Primary Endpoint In Patients With Newly Diagnosed Glioblastoma 67

Jun 09, 2011: Merck Serono Completes Patient Enrollment For Cilengitide’s Pivotal Phase III Trial CENTRIC 69

Aug 31, 2010: Stromedix Receives FDA Orphan Drug Designation For STX-100 For Treatment Of Idiopathic Pulmonary Fibrosis 69

Jun 05, 2010: EMD Serono Announces Long-Term Follow-up Data From Cilengitide Study In Glioblastoma Patients 70

May 31, 2009: Study Shows Cilengitide Increased Overall Survival In Patients With Glioblastoma 71

Mar 16, 2009: Merck Serono Expands Cilengitide Development Program 71

Jan 22, 2009: Stromedix Secures Broad Patent Coverage For Lead Program, Including Compositions Related To Its Lead Product, STX-100 72

Aug 12, 2008: Stromedix Receives Orphan Drug Designation For STX-100 In Chronic Allograft Nephropathy 72

Jan 01, 2004: 73

Appendix 74

Methodology 74

Coverage 74

Secondary Research 74

Primary Research 74

Expert Panel Validation 74

Contact Us 74

Disclaimer 75

List of Tables

List of Tables

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Comparative Analysis by Unknown Stage Development, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 17

Number of Products under Investigation by Universities/Institutes, H2 2016 18

Products under Investigation by Universities/Institutes, H2 2016 19

Assessment by Monotherapy/Combination Products, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 25

Pipeline by Biogen, Inc., H2 2016 26

Pipeline by BioMAS Ltd., H2 2016 27

Pipeline by MedImmune, LLC, H2 2016 28

Pipeline by Merck & Co., Inc., H2 2016 29

Pipeline by SciFluor Life Sciences, LLC, H2 2016 30

Pipeline by Tissue Therapies Limited, H2 2016 31

Pipeline by TWi Pharmaceuticals, Inc., H2 2016 32

Pipeline by Vascular Pharmaceuticals, Inc., H2 2016 33

Dormant Projects, H2 2016 57

Dormant Projects (Contd..1), H2 2016 58

Dormant Projects (Contd..2), H2 2016 59

Dormant Projects (Contd..3), H2 2016 60

Dormant Projects (Contd..4), H2 2016 61

Discontinued Products, H2 2016 62

Discontinued Products (Contd..1), H2 2016 63

List of Figures

List of Figures

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Top 10 Indication, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 21

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Molecule Types, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 24

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports